气体玻璃体溶解术缓解玻璃体黄斑牵拉
回顾性分析50眼症状性玻璃体黄斑牵拉接受0.3 mL全氟丙烷气体注射,单次注射后43眼(86.0%)发生玻璃体后脱离,中位时间3.0周;仅VMT眼80.0%发生PVD,小2期黄斑裂孔眼100%发生PVD且66.7%裂孔闭合,视力中位数从20/50改善至20/40(P < 0.001),作者认为该疗法可行但需更多研究明确适应证。
要点
- 单次0.3 mL C3F8注射后86.0%眼发生玻璃体后脱离,中位3.0周。
- 小2期黄斑裂孔眼PVD率100%,裂孔闭合率66.7%。
- 糖尿病和厚细胞膜者PVD率降低,年轻和基线视力好为预测因素。
核心结论
- 作者认为,限制性面朝下体位的气体玻璃体溶解术是治疗玻璃体黄斑牵拉的可行选择,不良事件少。
- 作者指出需要更多研究来阐明其适应证、获益和风险。
研究设计与样本
- 回顾性综述,纳入2010年至2016年连续49例患者(50眼)症状性玻璃体黄斑牵拉,接受0.3 mL全氟丙烷(C3F8)气体注射。
- 患者避免仰卧位直至气体吸收,小黄斑裂孔患者保持部分面朝下体位。
主要发现
- 单次气体注射后43眼(86.0%)发生玻璃体后脱离,中位时间3.0周。
- 仅VMT的35眼中28眼(80.0%)发生PVD,小2期黄斑裂孔15眼全部(100%)发生PVD,其中10眼(66.7%)裂孔闭合。
- 基线及末次最佳矫正视力中位数分别为20/50和20/40(P < 0.001),平均随访11.1 ± 9.9个月。
- 糖尿病者PVD率为25%,厚细胞膜者PVD率为50%。
- 单变量分析显示VMT范围在1个视盘面积内(χ = 13.1,P = 0.002)、无糖尿病(χ = 8.8,P = 0.007)、2期黄斑裂孔(χ = 5.47,P = 0.019)与VMT缓解增加相关;无厚细胞膜与成功之间存在趋势(χ = 3.32,P = 0.068)。
临床怎么用
- 作者认为,限制性面朝下体位的气体玻璃体溶解术是治疗VMT的可行选择,不良事件少。
- 作者指出需要更多研究来阐明其适应证、获益和风险。
局限性
- 作者指出需要更多研究来阐明其适应证、获益和风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the outcome of perfluoropropane (C3F8) gas injection for symptomatic vitreomacular traction (VMT) with or without Stage 2 macular hole (MH). METHODS: A retrospective review of eyes with VMT treated with 0.3 mL of C3F8 gas was performed. Patients avoided the supine position until gas resolution. Patients with small MH maintained partial face-down positioning. RESULTS: Forty-nine consecutive patients (50 eyes) with symptomatic VMT underwent pneumatic vitreolysis between 2010 and 2016. A posterior vitreous detachment developed in 43 eyes (86.0%) after a single gas injection, at a median of 3.0 weeks. Twenty-eight of 35 eyes (80.0%) with VMT only and all 15 eyes (100%) with a small Stage 2 MH developed a posterior vitreous detachment, with MH closure in 10 of 15 eyes (66.7%). Median baseline and last best spectacle-corrected visual acuities were 20/50 and 20/40, respectively (P < 0.001). Mean follow-up time was 11.1 ± 9.9 months. Rate of posterior vitreous detachment was reduced with presence of diabetes mellitus (25%) and with thick cellophane membrane (50%). Univariate analysis showed increased VMT release for eyes with VMT extent within 1 disk area (χ = 13.1, P = 0.002), eyes with absence of diabetes mellitus (χ = 8.8, P = 0.007), and eyes with Stage 2 MH (χ = 5.47, P = 0.019); there was a trend between success and lack of thick cellophane membrane (χ = 3.32, P = 0.068). Results using logistic regression also showed younger age (P = 0.012), followed by better baseline best spectacle-corrected visual acuity (P = 0.044), lack of diabetes mellitus (P = 0.077), and female gender (P = 0.045) to be predictors of increased VMT release. One VMT-only eye formed a MH and another VMT-only eye developed a retinal detachment. Both eyes responded to vitrectomy. CONCLUSION: Pneumatic vitreolysis with limited face-down position is a viable option for treating VMT with few adverse events. More studies are needed to elucidate its indications, benefits, and risks.
引用
- Chan CK, Crosson JN, Mein CE, et al. PNEUMATIC VITREOLYSIS FOR RELIEF OF VITREOMACULAR TRACTION. Retina. 2017. PMID: 28099316. doi:10.1097/IAE.0000000000001448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。